Soleus Capital Management, L.P.
About Soleus Capital Management, L.P.’s 13F portfolio
Soleus Capital Management, L.P. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Soleus Capital Management, L.P. reported $2.9B across 97 US-listed positions (). Its largest position is KRYSTAL BIOTECH INC (KRYS) at 12% of the reported book, and its ten biggest holdings make up 49% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: KRYS KRYSTAL BIOTECH INC | $315.82 +0.15% | 12% | 939K | $349.1M |
| 2 | NASDAQ: CELC CELCUITY INC | $56.31 +1.28% | 6.1% | 1.7M | $178.3M |
| 3 | NASDAQ: TGTX TG THERAPEUTICS INC | $64.88 −1.88% | 5.5% | 2.9M | $160.9M |
| 4 | NASDAQ: PODD INSULET CORP | $137.23 −1.96% | 5.5% | 1.0M | $159.7M |
| 5 | NASDAQ: NVCR NOVOCURE LTD | $10.69 −0.37% | 5.2% | 9.9M | $150.2M |
| 6 | NASDAQ: UTHR UNITED THERAPEUTICS CORP DEL | $559.10 −3.16% | 4.2% | 226K | $122.2M |
| 7 | NYSE: INSP INSPIRE MED SYS INC | $56.28 −3.15% | 3.0% | 1.9M | $86.2M |
| 8 | NASDAQ: RIGL RIGEL PHARMACEUTICALS INC | $41.19 −3.15% | 2.5% | 1.8M | $72.1M |
| 9 | NASDAQ: ANIP ANI PHARMACEUTICALS INC | $69.13 −3.27% | 2.5% | 868K | $71.8M |
| 10 | NASDAQ: BBNX BETA BIONICS INC | $13.32 −7.05% | 2.4% | 4.4M | $68.8M |
| 11 | NASDAQ: VCEL VERICEL CORP | $58.26 −0.66% | 2.2% | 1.5M | $64.9M |
| 12 | NASDAQ: PRAX PRAXIS PRECISION MEDICINES I | $310.90 +1.87% | 2.0% | 178K | $59.4M |
| 13 | NASDAQ: GERN GERON CORP | $0.91 −7.86% | 1.9% | 42.8M | $54.8M |
| 14 | NASDAQ: ALKS ALKERMES PLC | $46.18 −1.43% | 1.9% | 1.0M | $53.9M |
| 15 | NASDAQ: ERAS ERASCA INC | $14.22 +3.34% | 1.7% | 2.7M | $49.5M |
| 16 | NASDAQ: NPCE NEUROPACE INC | $8.14 −0.97% | 1.6% | 2.9M | $46.3M |
| 17 | NASDAQ: PGNY PROGYNY INC | $35.45 −1.96% | 1.6% | 1.6M | $46.2M |
| 18 | NASDAQ: INDV INDIVIOR PHARMACEUTICALS INC | $26.74 −5.21% | 1.5% | 1.1M | $43.7M |
| 19 | NASDAQ: PBLS PARABILIS MEDICINES INC | — — | 1.4% | 1.5M | $40.1M |
| 20 | NASDAQ: EDAP EDAP TMS S A | $5.44 −0.18% | 1.3% | 7.3M | $37.9M |
| 21 | NYSE: GMED GLOBUS MED INC | $68.60 −2.74% | 1.3% | 469K | $37.0M |
| 22 | NYSE: RCUS ARCUS BIOSCIENCES INC | $15.78 +0.13% | 1.2% | 1.2M | $36.0M |
| 23 | NASDAQ: SNDX SYNDAX PHARMACEUTICALS INC | $9.13 +6.66% | 1.2% | 1.6M | $35.6M |
| 24 | NASDAQ: NRIX NURIX THERAPEUTICS INC | $13.60 −3.55% | 1.2% | 1.5M | $35.5M |
| 25 | NASDAQ: LEGN LEGEND BIOTECH CORP | $16.10 −0.92% | 1.2% | 1.2M | $34.8M |
Showing 1–25 of 97 positions on this page reported in this 13F.
- Healthcare98%
- AddedCELCCELCUITY INC+32.7%$178.3M
- AddedPODDINSULET CORP+86.5%$159.7M
- AddedUTHRUNITED THERAPEUTICS CORP DEL+20.5%$122.2M
- AddedINSPINSPIRE MED SYS INC+235%$86.2M
- AddedRIGLRIGEL PHARMACEUTICALS INC+18335%$72.1M
- AddedANIPANI PHARMACEUTICALS INC+5.8%$71.8M
- AddedBBNXBETA BIONICS INC+0.9%$68.8M
- AddedGERNGERON CORP+3.1%$54.8M
- NewERASERASCA INC—$49.5M
- NewPBLSPARABILIS MEDICINES INC—$40.1M
- ReducedKRYSKRYSTAL BIOTECH INC−18.5%$349.1M
- ReducedTGTXTG THERAPEUTICS INC−27.3%$160.9M
- ReducedNVCRNOVOCURE LTD−5.5%$150.2M
- ReducedVCELVERICEL CORP−42.8%$64.9M
- ReducedPRAXPRAXIS PRECISION MEDICINES I−46.3%$59.4M
- ReducedALKSALKERMES PLC−47.8%$53.9M
- ReducedNPCENEUROPACE INC−0.7%$46.3M
- ReducedPGNYPROGYNY INC−22.5%$46.2M
- ReducedINDVINDIVIOR PHARMACEUTICALS INC−16.5%$43.7M
- ReducedGMEDGLOBUS MED INC−35.7%$37.0M
Reading Soleus Capital Management, L.P.’s 13F portfolio
Soleus Capital Management, L.P.’s $2.9B 13F book is spread across 97 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 49%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are KRYS, CELC, TGTX, PODD and NVCR, led by KRYSTAL BIOTECH INC (KRYS) at 12% of the portfolio. The heaviest sector exposure is Healthcare (98%).
What Soleus Capital Management, L.P. changed last quarter
Between 2026-03-31 and Q2 2026, Soleus Capital Management, L.P. was a net seller: it opened 22 new positions and added to 25 more, while trimming 41 and closing 18 outright. Against a 97-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was CELCUITY INC (CELC), and its biggest reduction was KRYSTAL BIOTECH INC (KRYS).
What a 13F does and doesn’t reveal
A 13F captures only Soleus Capital Management, L.P.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Soleus Capital Management, L.P. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Soleus Capital Management, L.P.'s profile on this page is built directly from those filings.
How current is the 13F data on Soleus Capital Management, L.P.'s page?
It reflects Soleus Capital Management, L.P.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Soleus Capital Management, L.P. files its next quarterly report, this page refreshes automatically.
Can I see Soleus Capital Management, L.P.'s complete list of holdings?
This page highlights Soleus Capital Management, L.P.'s largest positions rather than all 97 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Soleus Capital Management, L.P.'s filings.
Does a 13F show everything Soleus Capital Management, L.P. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Soleus Capital Management, L.P.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Soleus Capital Management, L.P. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

